Fagiolo U, Cancian M, Bertollo L, Peserico A, Amadori A
Institute of Internal Medicine, Department of Clinical Dermatology, University of Padova, Italy.
J Allergy Clin Immunol. 1999 Jun;103(6):1143-7. doi: 10.1016/s0091-6749(99)70190-9.
Most patients with chronic idiopathic urticaria (CIU) show cutaneous reactivity to intradermal injection of autologous serum. In some cases this reactivity is associated with the presence of autoantibodies directed against IgE or IgE receptors expressed on mast cells, whereas in others no autoimmune mechanisms can be documented.
The aims of this study were to compare the cutaneous reactivity to serum and plasma samples in a series of patients with active CIU and to address the mechanisms of the inhibitory effect exerted by heparin on the cutaneous responsiveness to the histamine-releasing factors (HRFs) present in CIU serum.
Fourteen patients with CIU were injected intradermally with autologous serum, plasma (anticoagulated by either heparin or EDTA), or serum samples to which heparin had been added. The effects of heparin injection on cutaneous responsiveness to allergens was tested in 5 atopic patients. Moreover, in a set of experiments sera were also adsorbed with Sepharose-conjugated heparin.
All the patients had positive cutaneous reactions to autologous serum injection. When heparinized plasma was injected, negative reactions were observed in 12 of 14 patients, and a sizable reduction in the wheal-and-flare reactions was recorded in the remaining 2. Compared with results obtained with serum, no substantial change was observed in 6 of 8 patients injected with EDTA-anticoagulated plasma. When heparin was added to serum, abrogation of skin reactivity was seen; nonetheless, no change in the cutaneous response to allergens was associated with locally administered heparin in 5 atopic patients with no history of CIU. Finally, adsorption of CIU sera with solid-phase heparin abrogated the ability to induce cutaneous reactions in 5 of 7 patients, whereas in the remaining 2 a sizable reduction was observed.
These data indicate that heparin is able to profoundly inhibit the cutaneous response to HRFs present in the sera of patients with CIU. Although the precise level of action of this heparin-mediated effect is unclear from present data, preliminary evidence seems to indicate that heparin could directly interfere with HRFs present in CIU sera.
大多数慢性特发性荨麻疹(CIU)患者对皮内注射自体血清表现出皮肤反应性。在某些情况下,这种反应性与针对肥大细胞上表达的IgE或IgE受体的自身抗体的存在有关,而在其他情况下,无法证明存在自身免疫机制。
本研究的目的是比较一系列活动性CIU患者对血清和血浆样本的皮肤反应性,并探讨肝素对CIU血清中组胺释放因子(HRF)皮肤反应性的抑制作用机制。
对14例CIU患者皮内注射自体血清、血浆(用肝素或乙二胺四乙酸抗凝)或添加了肝素的血清样本。在5例特应性患者中测试了肝素注射对皮肤对变应原反应性的影响。此外,在一组实验中,血清也用琼脂糖偶联肝素吸附。
所有患者对自体血清注射均有阳性皮肤反应。当注射肝素化血浆时,14例患者中有12例出现阴性反应,其余2例的风团和潮红反应有明显减轻。与血清注射结果相比,8例注射乙二胺四乙酸抗凝血浆的患者中有6例未观察到实质性变化。当向血清中添加肝素时,可以看到皮肤反应性消失;然而,在5例无CIU病史的特应性患者中,局部注射肝素与皮肤对变应原的反应无变化相关。最后,用固相肝素吸附CIU血清后,7例患者中有5例失去了诱导皮肤反应的能力,而其余2例则有明显减轻。
这些数据表明,肝素能够深刻抑制CIU患者血清中HRF的皮肤反应。尽管从目前的数据尚不清楚这种肝素介导作用的确切作用水平,但初步证据似乎表明,肝素可能直接干扰CIU血清中的HRF。